252 related articles for article (PubMed ID: 29172992)
21. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
Mugo N; Eckert LO; Odero L; Gakuo S; Ngure K; Celum C; Baeten JM; Barnabas RV; Wald A
Vaccine; 2021 Jul; 39(33):4751-4758. PubMed ID: 33485644
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Lebacq M; van der Most R; Moris P; Giannini SL; Schuind A; Datta SK; Descamps D;
Hum Vaccin; 2011 Dec; 7(12):1359-73. PubMed ID: 22048172
[TBL] [Abstract][Full Text] [Related]
23. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A
Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
[TBL] [Abstract][Full Text] [Related]
25. Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort.
Artemchuk H; Eriksson T; Poljak M; Surcel HM; Dillner J; Lehtinen M; Faust H
J Infect Dis; 2019 Jan; 219(4):582-589. PubMed ID: 30239832
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.
Ahn J; Peng S; Hung CF; Roden RBS; Best SR
Laryngoscope; 2018 Jan; 128(1):E16-E20. PubMed ID: 28868617
[TBL] [Abstract][Full Text] [Related]
27. Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries.
Gohar A; Abdeltawab NF; Shehata N; Amin MA
Papillomavirus Res; 2019 Dec; 8():100172. PubMed ID: 31185296
[TBL] [Abstract][Full Text] [Related]
28. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
Gilca V; Sauvageau C; Boulianne N; De Serres G; Crajden M; Ouakki M; Trevisan A; Dionne M
Hum Vaccin Immunother; 2015; 11(3):732-8. PubMed ID: 25714044
[TBL] [Abstract][Full Text] [Related]
29. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
[TBL] [Abstract][Full Text] [Related]
30. Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques.
Wang Y; Liu Y; Liang S; Yin F; Zhang H; Liu Y
Papillomavirus Res; 2020 Dec; 10():100209. PubMed ID: 33197649
[TBL] [Abstract][Full Text] [Related]
31. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
32. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
33. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
Front Immunol; 2020; 11():188. PubMed ID: 32133000
[TBL] [Abstract][Full Text] [Related]
34. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
[TBL] [Abstract][Full Text] [Related]
35. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults.
Giacomet V; Penagini F; Trabattoni D; Viganò A; Rainone V; Bernazzani G; Bonardi CM; Clerici M; Bedogni G; Zuccotti GV
Vaccine; 2014 Sep; 32(43):5657-61. PubMed ID: 25149430
[TBL] [Abstract][Full Text] [Related]
37. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial.
Pinto LA; Kemp TJ; Torres BN; Isaacs-Soriano K; Ingles D; Abrahamsen M; Pan Y; Lazcano-Ponce E; Salmeron J; Giuliano AR
J Infect Dis; 2016 Oct; 214(8):1276-83. PubMed ID: 27511896
[TBL] [Abstract][Full Text] [Related]
38. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
40. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
Money DM; Moses E; Blitz S; Vandriel SM; Lipsky N; Walmsley SL; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein M; Harris M; Cohen J; Wobeser W; Bitnun A; Lapointe N; Samson L; Brophy J; Karatzios C; Ogilvie G; Coutlée F; Raboud J;
Vaccine; 2016 Sep; 34(40):4799-806. PubMed ID: 27544584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
